ovarian

New Ovarian Cancer Study Is Released

Many important studies were presented last week at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Los Angeles, CA.  Among them were two studies that were covered in multiple media outlets, including the New York Times (click here to read the article).  The first study looked at more than 13,000 women with ovarian cancer and found that women are 30 percent less likely to die of ovarian cancer if they have guideline-recommended treatment.  Yet, nearly two-thirds of those women do not receive it.  Guidelines for ovarian cancer specify types of surgical procedures and chemotherapy, often the need for debulking surgery prior to chemotherapy.  The study found that surgeons who were more experienced in gynecologic oncology surgery, and hospitals that treated more women with ovarian cancer, were more likely to follow the guidelines, which translated to better outcomes for their patients.  The second study looked at the method of delivery of chemotherapy to patients.  Intraperitoneal (IP) chemotherapy, where chemotherapy drugs are pumped directly into the abdomen, utilizes the same chemotherapy agents often administered intravenously. While IP chemotherapy is more toxic, and logistically more complicated than IV chemotherapy, there is clearly a benefit in terms of survival rate.   

For you, the patient, these studies underscore the importance of making sure that you act as your own advocate by asking to be treated by a physician with ovarian cancer expertise and experience who practices according to available guidelines.  For ovarian cancer information and support, please call Sharsheret at 866.474.2774 or e-mail info@sharsheret.org

Ethan Wasserman, MD
Sharsheret Medical Advisory Board Member

THE VIEWS EXPRESSED ON THE BLOG ARE THOSE OF THE INDIVIDUAL USERS AND NOT NECESSARILY THE VIEWS OF SHARSHERET. ALTHOUGH SHARSHERET WILL BE MODERATING ALL MESSAGES POSTED TO THE BLOG, WE DO NOT CONFIRM OR WARRANT THE USEFULNESS, ACCURACY, OR COMPLETENESS OF ANY MESSAGES AND ARE NOT RESPONSIBLE FOR ANY DAMAGE OR LOSS RELATED TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION. SHARSHERET DOES NOT MAKE ANY EXPRESSED OR IMPLIED WARRANTIES WITH REGARD TO INFORMATION OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTIES OF TITLE OR NON-INFRINGEMENT. IN NO EVENT SHALL THE PROVIDERS BE LIABLE TO YOU OR A THIRD PARTY FOR ANY ACTION, OR FAILURE TO ACT BASED ON RELIANCE ON THE CONTENT POSTED ON THE BLOG. ALL INFORMATION IS PROVIDED WITHOUT ANY WARRANTY OF ANY KIND.

Helping Us Help You

By: Ruthie Arbit, Sema Heller Netivot Shalom Summer Intern

After 10 weeks of interning at Sharsheret, I can safely say that I went from a state of bewilderment from when I initially heard about Sharsheret in April to a state of admiration. Then, I was struck by the cause; I didn’t know that breast cancer and ovarian cancer were Jewish issues and I wondered what Sharsheret was doing to help Jewish women facing these illnesses. Now, I am in awe as I think about the callers, the peer supporters, and the volunteers who help us at Sharsheret do what we do.

The Sharsheret office is an incredible place. On any given day there is a string of devoted volunteers popping in and out, Team Sharsheret athletes coming in to meet with the staff, and the daily visit by the postman who picks up packages filled with hundreds of breast cancer and ovarian cancer brochures to be delivered to women and families, health care professionals, conferences, and Jewish organizations nationwide. Add all of this to the hard work that the dedicated staff at Sharsheret puts in – providing emotional support to women living with cancer and their families, answering countless questions from health care professionals about the unique needs of their Jewish patients, planning outreach events to spread the word about Sharsheret’s programs and services, coordinating medical symposia, and processing generous contributions from donors. It’s no surprise then that after only 10 years since its inception, Sharsheret has become an esteemed national organization with 11 programs, more than 1,200 peer supporters, and thousands of volunteers and supporters.

However, what impresses me most about Sharsheret are the women. The women who call Sharsheret for support as they ponder the potentially life-changing decision of whether or not to undergo genetic testing, the women who have just finished their final round of chemo and are already volunteering to be peer supporters, and those who are living with metastatic cancer and finding value in every day moments.

All of these women amaze me.

So, as I near the end of my internship, I want to say thank you to the women whose strength fuels the energy of Sharsheret. I am sure that this won’t be the last time I will be surprised by the amazing work of Sharsheret, its staff, and its women. Although my internship is ending, my connection to Sharsheret will remain strong. I look forward to joining Sharsheret’s volunteer force and contributing my time and skills to this wonderful organization.